Dupilumab adverse reactions in eosinophilic esophagitis treatment: a Food and Drug Administration Adverse Event Reporting System database analysis
Diseases of the Esophagus · 03.07.2025 · 38 (4)
DOI: 10.1093/dote/doaf055 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diseases of the Esophagus, online erschienen am 15.07.2025. Verfasst von Kasey Bowyer und 3 weiteren Autor:innen. Beteiligte Einrichtung: Kaiser Permanente Bernard J. Tyson School of Medicine, Kaiser Permanente, Pasadena, CA, USA. Hauptthemen laut MEDLINE: Eosinophilic Esophagitis, Antibodies, Monoclonal, Humanized, Adverse Drug Reaction Reporting Systems, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Abstract (Originalsprache)
Dupilumab, the first biologic approved for eosinophilic esophagitis treatment (EoE-tx) in 2022, demonstrated favorable safety in phase-III clinical trials. However, real-world dupilumab-associated adverse reactions (DARs) for EoE-tx are unknown. This study aims to evaluate DAR for EoE-tx using the FDA Adverse Event Reporting System. FDA Adverse Event Reporting System was queried for DAR between 2022Q1 and 2023Q4. Individual DARs (iDARs) were categorized and compared between treatment groups: EoE, asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps. Logistic regression was used to predict serious DAR and outcomes, and zero-truncated negative binomial regression was used to predict the number of iDAR. There were 51,000 DAR observations; 1459 for EoE-tx with 103 (7.1%) serious reactions and 44 (3.0%) serious outcomes including 3 deaths. For EoE-tx, the mean iDAR was 3.68 [3.51, 3.85], and the iDAR incidence rate ratio among men receiving EoE-tx was 0.73 [0.65, 0.83]. EoE-tx average iDAR primarily included general (0.75 [0.70, 0.80]), injection-site (0.69 [0.63, 0.74]), dermatologic (0.51 [0.46, 0.55]), and gastrointestinal (0.24 [0.21, 0.27]) reactions. Adults ≥50 years had 1.97 [1.28, 2.99] higher odds for serious DAR compared to younger adults in EoE-tx. Overall, dupilumab demonstrated a favorable safety profile across all indications, with low rates of serious adverse events. For EoE-tx specifically, higher total iDAR rates were observed, driven largely by increased injection-site and gastrointestinal reactions compared to other indications. Additionally, women exhibited higher iDAR rates than men across all indications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Kaiser Permanente Bernard J. Tyson School of Medicine, Kaiser Permanente, Pasadena, CA, USA.
- Department of Otolaryngology-Head and Neck Surgery, Mayo Clinic Arizona, Scottsdale, AZ, USA.
- Department of Otolaryngology-Head and Neck Surgery, Kaiser Permanente, Oakland, CA, USA.
ORCID-Profile: Kasey Bowyer
Zitieren
APA
Bowyer, K., Swisher, A. R., Jiang, N., & Liang, J. (2025). Dupilumab adverse reactions in eosinophilic esophagitis treatment: a Food and Drug Administration Adverse Event Reporting System database analysis. Diseases of the Esophagus, 38(4). https://doi.org/10.1093/dote/doaf055
Vancouver
Bowyer K, Swisher AR, Jiang N, Liang J. Dupilumab adverse reactions in eosinophilic esophagitis treatment: a Food and Drug Administration Adverse Event Reporting System database analysis. Diseases of the Esophagus. 2025;38(4). doi:10.1093/dote/doaf055
BibTeX
@article{Bowyer2025,
author = {Bowyer, Kasey and Swisher, Austin R and Jiang, Nancy and Liang, Jonathan},
title = {Dupilumab adverse reactions in eosinophilic esophagitis treatment: a Food and Drug Administration Adverse Event Reporting System database analysis},
journal = {Diseases of the Esophagus},
year = {2025},
volume = {38},
number = {4},
doi = {10.1093/dote/doaf055}
}
EUVIMED